Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes

BMC Medical Imaging

Volumn 13, Issue 1, 2013, Pages

  Motomura, Kazuyoshi ^a   Izumi, Tetsuta ^a   Tateishi, Souichirou ^a   Sumino, Hiroshi ^a   Noguchi, Atsushi ^a   Horinouchi, Takashi ^a   Nakanishi, Katsuyuki ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Breast cancer; Computed tomography; Lymph node metastasis; Magnetic resonance imaging; Nodal enhancement pattern; Sentinel node; Superparamagnetic iron oxide

Indexed keywords

CONTRAST MEDIUM; DEXTRAN; FERUMOXTRAN-10; MAGNETITE NANOPARTICLE; DIAGNOSTIC AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; HUMAN; IMAGE GUIDED BIOPSY; JAPAN; LYMPH NODE METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; SECONDARY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; STATISTICS AND NUMERICAL DATA; TUMOR VOLUME; ARTICLE; BREAST TUMOR; METASTASIS; METHODOLOGY; STATISTICS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CONTRAST MEDIA; DEXTRANS; FEMALE; HUMANS; IMAGE-GUIDED BIOPSY; JAPAN; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84883696021     PISSN: None     EISSN: 14712342     Source Type: Journal    
DOI: 10.1186/1471-2342-13-32     Document Type: Article

References (24)

1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220:391-401.
2. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15:2345-2350.
3. Motomura K, Inaji H, Komoike Y, Kasugai T, Nagumo S, Noguchi S, Koyama H. Sentinel node biopsy in breast cancer patients with clinically negative lymph-nodes. Breast Cancer 1999, 6:259-262.
4. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 1998, 339:941-946.
5. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, de Cicco C, Geraghty JG, Luini A, Sacchini V, Veronesi P. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997, 349:1864-1867.
6. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006, 13:491-500.
7. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE. American College of Surgeons Oncology Group: Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007, 25:3657-3663.
8. McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008, 26:5213-5219.
9. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
10. Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, Oram DH, Jacobs IJ, Shepherd JH, Reznek RH. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005, 23:2813-2821.
11. Stets C, Brandt S, Wallis F, Buchmann J, Gilbert FJ, Heywang-Köbrunner SH. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging 2002, 16:60-68.
12. Will O, Purkayastha S, Chan C, Athanasiou T, Darzi AW, Gedroyc W, Tekkis PP. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 2006, 7:52-60.
13. Motomura K, Ishitobi M, Komoike Y, Koyama H, Noguchi A, Sumino H, Kumatani Y, Inaji H, Horinouchi T, Nakanishi K. SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann Surg Oncol 2011, 18:3422-3429.
14. Ohno Y, Hatabu H, Takenaka D, Higashino T, Watanabe H, Ohbayashi C, Sugimura K. CT-guided transthoracic needle aspiration biopsy of small (< or = 20 mm) solitary pulmonary nodules. AJR Am J Roentgenol 2003, 180:1665-1669.
15. Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 2002, 23:649-656.
16. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempany CM. Group Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003, 228:777-788. Group.
17. Motomura K, Inaji H, Komoike Y, Hasegawa Y, Kasugai T, Noguchi S, Koyama H. Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol 2001, 76:95-99.
18. Motomura K, Komoike Y, Hasegawa Y, Kasugai T, Inaji H, Noguchi S, Koyama H. Intradermal radioisotope injection is superior to subdermal injection for the identification of the sentinel node in breast cancer patients. J Surg Oncol 2003, 82:91-96.
19. Motomura K, Nagumo S, Komoike Y, Koyama H, Inaji H. Accuracy of imprint cytology for intraoperative diagnosis of sentinel node metastases in breast cancer. Ann Surg 2008, 247:839-842.
20. et al. American Joint Committee on Cancer Breast. AJCC Cancer Staging Handbook 2002, 155-181. New York: Springer, Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, 6, American Joint Committee on Cancer.
21. Lahaye MJ, Engelen SM, Kessels AG, de Bruïne AP, von Meyenfeldt MF, van Engelshoven JM, van de Velde CJ, Beets GL, Beets-Tan RG. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008, 246:804-811.
22. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361:653-663.
23. de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC. Breast cancer prognosis lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010, 102:410-425.
24. Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, Giuliano AE. Impact of in the sentinel node of patients with invasive breast cancer. J Clin Oncol 2009, 27:4679-4684.